Universität Bern
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 6 name spellings.
4
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Jan 2 to 25, 2027 · next Jan 2
- 2 fees due Feb 27, 2027
- 2 fees due Mar 10 to 17, 2027 · next Mar 10
- 1 fee due Apr 13, 2027The maintenance fee for Method of determining the genotype relating to hereditary nasal parakeratosis (HNPK) and nucleic acids usable in said method (US 9,157,114) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
- 2 fees due Sep 5 to 8, 2027 · next Sep 5
- 1 fee due Oct 21, 2027The maintenance fee for Inositol Derivatives for Use in Pathological Crystallization (US 10,624,909) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 23, 2026
- Nov 10 US 12,792,627 Information Retrieval And/Or Visualization Method
- Sep 22 US 12,740,699 Method for Obtaining a Visual Field Map of an Observer
- Aug 25 US 12,717,876 Asynchronous Intercorrelated Time Series Datasets Alignment Method
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,655,300 | Transparent Zeolite-Polymer Hybrid Material with Tunable Properties In force · High confidence | In force | High confidence | |
| US 8,501,687 | RECEPTOR(SSTR2)-SELECTIVE Somatostatin Antagonists In force · High confidence | In force | High confidence | |
| US 8,691,761 | Somatostatin Receptor 2 Antagonists In force · High confidence | In force | High confidence | |
| US 9,763,979 | Cardioplegic preparation In force · USPTO record | In force | USPTO record | |
| US 8,885,906 | Alignment of positron emission tomographs by virtual tomographs In force · USPTO record | In force | USPTO record | |
| US 9,522,184 | CD89 activation in therapy In force · USPTO record | In force | USPTO record | |
| US 9,738,891 | Tricyclo-Phosphorothioate DNA In force · High confidence | In force | High confidence | |
| US 9,546,209 | Treatment of mucositis with immunoglobulin In force · USPTO record | In force | USPTO record | |
| US 9,277,861 | Automatic image optimization system, particularly for stereomicroscopes In force · USPTO record | In force | USPTO record | |
| US 10,342,622 | System and method for estimating the spatial position of a tool within an object In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 54: 15 patents in force now held by others · 23 lapsed for an unpaid fee · 13 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
24 pending · 14 abandoned · 38 no status recorded
Rows 11 to 60 of 76 are for members. The first 10 are on the company page.
Pro members see all 76 published applications.